Acquired Immunodeficiency Syndrome

The Research Foundation to Cure AIDS has purchased licensing rights to Chromovert, a cell-based biotechnology that detects and purifies rare cells.

In this video, Ya-Chi Ho, MD, MS, PhD, instructor of medicine at the Johns Hopkins University School of Medicine and co-leader of the HIV Cure Scientific Working Group at the Johns Hopkins Center for AIDS Research, reviews the approaches to HIV cure that were discussed at ASM Microbe 2016.

The role of ART in treating and preventing HIV was the focus of several presentations at ASM Microbe 2016. The use of these regimens among older patients and individuals with renal impairment was highlighted, as well as the ways in which the Strategic Timing of Antiretroviral Treatment trial has impacted initiation of therapy for all patients with HIV.

There are several mechanisms that contribute to HIV persistence, all of which may influence the ability to develop a cure, according to Jonathan Z. Li, MD, MMSc, assistant professor of medicine at Harvard Medical School and Brigham and Women’s Hospital and member of the AIDS Clinical Trials Group at Brigham and Women’s Hospital.

In this video, Daniel Kuritzkes, MD, principal investigator of the AIDS Clinical Trials Group and chief of infectious diseases at Brigham and Women's Hospital and professor of medicine at Harvard Medical School, reviews the different areas covered in the session on HIV cure at ASM Microbe 2016.

In recent years, a “big emphasis” in the treatment of HIV has been placed on the development of tenofovir alafenamide and the increasing number of combination regimens, according to Ann Collier, MD, professor of medicine in the division of allergy and infectious diseases and director of the AIDS Clinical Trials Unit at the University of Washington and associate director of the Center for AIDS Research at the University of Washington and Fred Hutchinson Cancer Research Center.

In recent years, “a great deal of interest” has been generated around simplifying ART regimens, according to Daniel Kuritzkes, MD, principal investigator of the AIDS Clinical Trials Group and chief of infectious diseases at Brigham and Women's Hospital and professor of medicine at Harvard Medical School.

In this video with Healio.com, Robert Harrington, MD, of the University of Washington School of Medicine and Harborview Medical Center in Seattle, reviews the role of the Ryan White Care Act in providing health care to patients with HIV as well as the future of the program with the enactment of the Affordable Care Act (ACA).

The health disparities associated with HIV have been underscored, and even heightened, in some areas of the United States with the uneven rollout of the Affordable Care Act, according to Chris Beyrer, MD, professor of epidemiology, Johns Hopkins Bloomberg School of Public Health, co-director, Johns Hopkins Center for AIDS Research, and president, International AIDS Society.

The use of pre-exposure prophylaxis, or PrEP, in women is “a little bit more complicated” compared with men, according to Raphael J. Landovitz, MD, of the UCLA Center for Clinical AIDS Research and the David Geffen School of Medicine at UCLA.